FDA Approves Tregzi, First Regulatory T‑Cell Immunotherapy to Reduce Chronic GVHD After Donor Stem‑Cell Transplants
FDA clears Tregzi (Orca‑T), the first regulatory T‑cell immunotherapy, to lower chronic graft‑versus‑host disease after donor stem‑cell transplantation.